Secretin, Unspecified

Dosage for Secretin, Unspecified is highly individualized and is based on the method of administration and the patient's sensitivity levels.

Skin Prick Testing (SPT)

For initial screening, a single drop of the concentrated extract (typically 1:20 w/v) is applied to the skin, followed by a prick or puncture through the drop into the epidermis. This introduces approximately 0.001 to 0.005 mL of the extract into the skin.

Intradermal Testing (IDT)

If the skin prick test is negative but clinical suspicion remains high, an intradermal test may be performed. The healthcare provider injects 0.02 to 0.05 mL of a 1:100 or 1:1000 dilution into the dermis, creating a small bleb (bubble).

Secretin, Unspecified may be used in children, but the procedure must be performed with extreme caution.

• Children (under 12 years): The procedure is similar to adults, but the number of simultaneous tests may be limited to reduce the risk of systemic absorption.
• Infants: Testing is rarely performed in infants unless there is a critical diagnostic need for a secretin stimulation test and a high risk of anaphylaxis.
• Dosage Adjustment: No specific dose adjustment is required, but smaller volumes (0.01 mL) may be used for intradermal blebs to minimize discomfort and systemic risk.

Renal Impairment

No dosage adjustment is necessary for patients with kidney disease, as the amount of protein administered is negligible and does not rely on renal clearance for its diagnostic effect. However, patients with end-stage renal disease may have altered skin reactivity (uremic pruritus), which can interfere with result interpretation.

Hepatic Impairment

No dosage adjustment is required for patients with liver disease. The metabolic breakdown of the small amount of protein used in skin testing is not significantly affected by hepatic function.

Elderly Patients

In elderly patients (over 65), skin reactivity may be diminished due to age-related changes in skin elasticity and mast cell density. Healthcare providers may need to use a more concentrated extract or rely more heavily on the histamine control to ensure the test is valid.

Secretin, Unspecified is never self-administered. It must be administered by a trained healthcare professional in a clinical setting equipped to handle anaphylaxis.

1. 1Preparation: The skin (usually the forearm or back) is cleaned with isopropyl alcohol and allowed to dry.
2. 2Application: The extract is applied via the prick or intradermal method.
3. 3Observation: The patient must remain in the office for at least 30 minutes after the test.
4. 4Measurement: At the 15-20 minute mark, the healthcare provider will measure the diameter of any wheal and flare that has developed.
5. 5Storage: The extract should be stored in a refrigerator at 2°C to 8°C (36°F to 46°F). It should not be frozen.

Since this is a diagnostic test performed during a scheduled office visit, missed doses are not applicable in the traditional sense. If a testing appointment is missed, it should be rescheduled as soon as possible to complete the diagnostic workup.

An 'overdose' in the context of skin testing refers to the administration of too much extract or using a concentration that is too high for a highly sensitive patient.

• Signs of Overdose: Rapid development of a very large wheal (over 15-20 mm), generalized itching, hives (urticaria) away from the test site, swelling of the lips or throat, wheezing, or a drop in blood pressure.
• Emergency Measures: If a systemic reaction occurs, the healthcare provider will immediately administer epinephrine (adrenaline) and may follow with antihistamines, corticosteroids, and oxygen. Emergency medical services (911) should be contacted if the reaction occurs outside a hospital setting.

> Important: Follow your healthcare provider's instructions regarding the discontinuation of antihistamines before testing. Do not attempt to interpret skin test results yourself.

The most common side effects of Secretin, Unspecified are localized to the site of administration. These are often expected as part of a positive test result.

• Local Pruritus (Itching): A sharp, localized itching at the site of the prick or injection. This typically begins within 5 minutes and peaks at 15-20 minutes.
• Wheal Formation: A raised, pale, or skin-colored bump at the test site. It may feel firm to the touch.
• Erythema (Flare): A redness of the skin surrounding the wheal. This can range from a few millimeters to several centimeters in diameter.
• Local Warmth: The test site may feel warm to the touch due to increased blood flow.

These local symptoms usually resolve within 1 to 2 hours without treatment, although residual redness may persist for up to 24 hours.

• Delayed Local Reaction: Swelling and redness that reappears or worsens 4 to 8 hours after the initial test. This is known as a 'late-phase reaction.'
• Local Pain: A mild stinging or burning sensation at the site of the intradermal injection.
• Bruising: Small amounts of bleeding under the skin (ecchymosis) at the injection site, particularly in patients taking blood thinners.

• Lymphangitis: Red streaks extending from the test site toward the lymph nodes (very rare with diagnostic testing).
• Syncope (Fainting): A vasovagal response to the needle prick or the sight of blood, rather than an allergic reaction to the extract itself.

While rare during skin testing, systemic allergic reactions can occur. These require immediate medical intervention.

> Warning: Stop the procedure and call for emergency help if you experience any of the following:

• Anaphylaxis: A severe, life-threatening systemic allergic reaction. Symptoms include a rapid pulse, difficulty breathing, and a sharp drop in blood pressure.
• Angioedema: Deep swelling under the skin, particularly around the eyes, lips, tongue, or throat. This can obstruct the airway.
• Generalized Urticaria: Hives that spread to parts of the body far away from the test site.
• Bronchospasm: Tightness in the chest, wheezing, or a persistent cough, indicating that the airways are narrowing.
• Hypotension: Feeling dizzy, lightheaded, or fainting due to low blood pressure.

There are no known long-term side effects associated with a single diagnostic exposure to Secretin, Unspecified. Unlike therapeutic allergenic extracts used in immunotherapy (allergy shots), diagnostic extracts are not administered repeatedly over long periods. There is no evidence that skin testing with secretin causes the development of new allergies or long-term organ damage.

While Secretin, Unspecified may not have a specific black box warning for the 'unspecified' extract, all allergenic extracts carry a general class warning regarding the risk of severe systemic reactions.

FDA Class Warning for Allergenic Extracts:

"Allergenic extracts can cause severe life-threatening systemic reactions, including anaphylaxis. Patients should be observed for at least 30 minutes following administration. Epinephrine must be immediately available. Patients with unstable asthma or those taking beta-blockers may be at increased risk for severe outcomes."

Report any unusual symptoms or delayed reactions to your healthcare provider immediately.

Secretin, Unspecified must be used only for diagnostic purposes by clinicians trained in the management of allergic diseases. The primary safety concern is the potential for an immediate systemic allergic reaction. Patients must provide a full medical history, including previous reactions to animal-derived products, before undergoing testing.

No specific FDA black box warning exists uniquely for 'Secretin, Unspecified,' but it falls under the mandatory class warnings for all allergenic extracts. These warnings emphasize that these products are not for self-administration and require a clinical setting where emergency resuscitative equipment is available.

• Anaphylaxis Risk: The risk is highest in patients with a history of severe asthma or those who have had previous systemic reactions to secretin or porcine products. Testing should be postponed if the patient's asthma is not well-controlled.
• Beta-Blocker Use: Patients taking beta-blockers (e.g., metoprolol, propranolol) may be resistant to the effects of epinephrine if an allergic reaction occurs. This can make anaphylaxis much more difficult to treat.
• Dermatographism: Some patients have 'skin writing' disease, where any pressure on the skin causes a hive. This can lead to false-positive results. A saline control is essential to rule this out.
• Acute Illness: Testing should be deferred if the patient is suffering from an acute infection or fever, as this can alter immune reactivity.

• Post-Test Observation: The patient must be monitored visually for at least 30 minutes after the extract is applied. Vital signs (blood pressure, heart rate) may be checked if the patient feels unwell.
• Peak Flow Monitoring: For patients with asthma, a peak flow meter may be used before and after testing to ensure no bronchospasm has occurred.

Secretin, Unspecified testing does not typically interfere with the ability to drive or operate machinery. However, if a patient experiences a vasovagal response (fainting) or a systemic reaction requiring medication (like diphenhydramine), they should not drive until the effects have completely worn off.

There is no direct interaction between alcohol and Secretin, Unspecified. However, alcohol consumption can cause vasodilation and may slightly increase the size of a skin test reaction or exacerbate a systemic allergic response. It is generally advised to avoid alcohol for 24 hours before and after allergy testing.

Since this is a one-time diagnostic test, there is no 'discontinuation' or 'withdrawal' process. However, patients must stop taking certain medications (like antihistamines) several days before the test for the results to be valid.

> Important: Discuss all your medical conditions, especially heart disease or asthma, with your healthcare provider before starting Secretin, Unspecified testing.

There are no absolute drug-drug contraindications that prevent the use of Secretin, Unspecified, but certain medications make the test dangerous or impossible to interpret.

• Systemic Epinephrine: If a patient is already receiving epinephrine for another condition, the skin test results will be suppressed, and the diagnostic value is lost.

• Beta-Adrenergic Blockers: These drugs (e.g., atenolol, carvedilol) can increase the severity of anaphylaxis and block the life-saving effects of epinephrine. Healthcare providers must weigh the risk/benefit ratio carefully.
• ACE Inhibitors: Some evidence suggests that patients on ACE inhibitors (e.g., lisinopril) may experience more severe or frequent systemic reactions to allergenic extracts.
• TCAs and MAOIs: Certain antidepressants, such as Amitriptyline or Phenelzine, can interfere with the body's response to epinephrine or significantly suppress the skin's histamine response, leading to false negatives.

• Antihistamines (H1 Blockers): Drugs like loratadine (Claritin), cetirizine (Zyrtec), and diphenhydramine (Benadryl) MUST be stopped 3 to 7 days before testing. They block the H1 receptors in the skin, preventing the wheal and flare reaction even if the patient is allergic.
• H2 Blockers: Medications like famotidine (Pepcid) or cimetidine (Tagamet) can also mildly suppress skin reactivity and should be discontinued 48 hours before testing.
• Topical Corticosteroids: Applying steroid creams to the test site will suppress the local immune response. These should be avoided for at least 2-3 weeks on the specific area of skin to be tested.

There are no specific food interactions that affect the pharmacology of Secretin, Unspecified. However, patients should avoid consuming large amounts of high-histamine foods (like aged cheeses or fermented products) immediately before testing, as this could theoretically increase skin sensitivity.

• High-Dose Vitamin C: Some studies suggest very high doses of Vitamin C may have a mild antihistamine effect, potentially dampening the skin test response.
• St. John's Wort: May interact with other medications used to treat allergic reactions.

Secretin, Unspecified does not interfere with standard blood chemistry or hematology tests. However, its use is intended to supplement or confirm other diagnostic tests, such as Serum Tryptase (measured if anaphylaxis occurs) or Specific IgE blood tests (ImmunoCAP).

> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking, especially any 'allergy' or 'cold' medicines.

Secretin, Unspecified should NEVER be used in the following circumstances:

1. 1Recent Systemic Allergic Reaction: If a patient has experienced anaphylaxis from any cause within the last 4 weeks, skin testing should be delayed. The body's mast cells may be 'exhausted' (in a refractory period), leading to a false-negative result.
2. 2Severe, Uncontrolled Asthma: Patients with an FEV1 (Forced Expiratory Volume) of less than 70% of their predicted value are at an unacceptably high risk for fatal bronchospasm during testing.
3. 3History of Severe Reaction to Secretin: If a patient has previously had a life-threatening reaction to a secretin stimulation test, skin testing may be too dangerous unless performed in a highly controlled 'graded challenge' format.

• Pregnancy: While not strictly forbidden, elective diagnostic skin testing is usually postponed until after delivery to avoid any risk of anaphylaxis-induced fetal distress.
• Generalized Dermatitis or Eczema: If the skin is inflamed or covered in lesions, there may be no 'clear' skin available for testing, and the results will be unreliable.
• Beta-Blocker Therapy: As noted, this complicates the treatment of potential side effects.

Patients with known allergies to the following should be tested with extreme caution:

• Porcine-derived products (e.g., certain insulins, pancreatic enzymes).
• Bovine-derived products.
• Other gastrointestinal hormones (e.g., Cholecystokinin).

> Important: Your healthcare provider will evaluate your complete medical history before prescribing Secretin, Unspecified testing.

Secretin, Unspecified is generally categorized as Pregnancy Category C. There are no adequate and well-controlled studies in pregnant women. The primary risk is not the extract itself, but the potential for a systemic allergic reaction (anaphylaxis) in the mother. Anaphylaxis can cause a sudden drop in maternal blood pressure, leading to placental hypoperfusion (reduced blood flow to the baby) and fetal hypoxia (lack of oxygen). For this reason, diagnostic skin testing is typically deferred until the postpartum period unless the diagnosis is critical for the mother's immediate health.

It is not known whether the protein components of Secretin, Unspecified are excreted in human milk. However, because the amount used in skin testing is so small and the proteins are rapidly degraded, it is highly unlikely to affect a nursing infant. Most experts consider diagnostic skin testing compatible with breastfeeding.

Secretin, Unspecified is safe for use in children when administered by a specialist. The main challenge in pediatric populations is the physical discomfort of the needle pricks and the requirement for the child to remain still. In very young children, the number of tests is kept to a minimum. There is no evidence that diagnostic testing affects growth or development.

In patients over 65, the skin's immunological 'reactivity' tends to decrease. This can result in smaller wheal sizes, making it harder to distinguish a positive result from a negative one. Additionally, elderly patients are more likely to have underlying cardiovascular disease, which increases the risk if a systemic reaction occurs. Healthcare providers should carefully monitor heart rate and blood pressure in this population.

As previously discussed, renal impairment does not significantly alter the use of Secretin, Unspecified. However, patients on dialysis may have 'itchy skin' (uremic pruritus) which can make the interpretation of a 'flare' (redness) difficult. The use of a negative saline control is mandatory in these patients.

Liver disease does not affect the safety or efficacy of Secretin, Unspecified skin testing. No dose adjustments are required for patients with cirrhosis or hepatitis.

> Important: Special populations require individualized medical assessment and a cautious approach to diagnostic testing.

Secretin, Unspecified acts as an antigen. Upon introduction into the skin, it seeks out mast cells that have been 'sensitized' with IgE antibodies. The molecular mechanism involves the binding of the secretin protein to the Fab portion of the IgE molecule. When two IgE molecules are cross-linked by a single secretin protein, the high-affinity IgE receptor (FcεRI) on the mast cell triggers an intracellular signaling cascade involving tyrosine kinases (like Syk). This results in the release of pre-formed mediators (histamine) and the de novo synthesis of lipid mediators. These mediators act on H1 receptors on local blood vessels to cause the diagnostic 'wheal and flare.'

• Onset of Action: The local allergic response begins almost immediately, with visible redness appearing within 2-5 minutes.
• Peak Effect: The wheal and flare typically reach their maximum size between 15 and 20 minutes.
• Duration: The primary reaction fades within 1-2 hours, though a late-phase reaction (mediated by eosinophils and T-cells) can occur 4-12 hours later.

| Parameter | Value |

|---|---|

| Bioavailability | Negligible (Local) |

| Protein Binding | High (to IgE) |

| Half-life | ~20 minutes (local reaction) |

| Tmax | 15-20 minutes |

| Metabolism | Proteolysis by local proteases |

| Excretion | Renal (as peptides) |

• Molecular Formula: Complex protein structure (primarily porcine or bovine secretin sequences).
• Molecular Weight: Approximately 3,055 Daltons (for the 27-amino acid peptide).
• Solubility: Soluble in aqueous buffers and saline.
• Structure: A single-chain polypeptide consisting of 27 amino acids. In 'unspecified' extracts, this peptide is contained within a mixture of other proteins derived from the source tissue.

Secretin, Unspecified is classified as a Non-Standardized Allergenic Extract. It belongs to the broader category of diagnostic biologicals. Related medications include standardized extracts (like Grass Pollen or Dust Mite) and other non-standardized food or hormone extracts.